Also found in: Dictionary, Thesaurus, Medical, Encyclopedia.
CUTICámara Uruguaya de Tecnologías de la Información (Spanish)
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
Under a cost-sharing contract, BARDA and VenatoRx will share the costs of all studies needed to bring the drug to market, including planned pivotal Phase 3 clinical trials to treat cUTI, hospital-acquired and ventilator-associated bacterial pneumonia, carbapenem-resistant pathogens and a data package to potentially support the use of cefepime/VNRX-5133 in the treatment of melioidosis and glanders.
Understanding the prevalence, disease pattern and response of the patients of the cUTI to the antibiotic combination therapy will help guide to the appropriate level of suspicion and appropriate work for the UTIs.
Meanwhile, the provosts of the Kwara State Colleges of Education Ilorin, Oro and Lafiagi have appealed to the Committee of Union of Tertiary Institutions (CUTI) to suspend its ongoing industrial strike.
Cuti's attorney in the civil case, Jeffrey Sklaroff, said in a statement released the day after the indictments came down that the transactions were disputed and had no effect on stockholders, bondholders, the company or Oak Hill.
Cuti has its church, but the people rarely see a priest, a sister or a lay catechist.
We look forward to the opportunity to bring this important treatment to patients as quickly as possible and providing clinicians an urgently needed early and appropriate therapeutic option to manage patients at risk of resistant infections with limited available treatment options for cUTIs,' said Ted Schroeder, Chief Executive Officer of Nabriva Therapeutics.
The US FDA approved the product to treat patients 18 years of age and older who have limited or no alternative treatment options for cUTI, including pyelonephritis, caused by susceptible Gram-negative microorganisms such as Enterobacter cloacae, Escherichia coli, Klebsiella aerogenes, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
The US Food and Drug Administration (FDA) on Wednesday cleared the marketing of the antibacterial drug Recarbrio (imipenem, cilastatin and relebactam), for adults with complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI) under its Qualified Infectious Disease Product (QIDP) designation & Priority Review designations.
These new designations augment Iterum's existing QIDP designations for oral and IV sulopenem for the treatment of uncomplicated urinary tract infection, or uUTI, complicated urinary tract infection, or cUTI, and complicated intra-abdominal infection, or cIAI, which the FDA granted in 2017.